Nuclea taps Enzo to distribute metastatic breast cancer test

02/19/2014 | GenomeWeb Daily News (free registration)

Nuclea Biotechnologies has agreed to allow Enzo Clinical Labs to offer its HER-2/neu serum assay for undisclosed terms. The assay, which uses blood samples, is designed to help doctors monitor metastatic breast cancer in women whose tumors contain the HER-2/neu protein and make treatment decisions based on the outcomes.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN